Gabriel Araújo Medeiros, Jan B Felinto de Santana, Lenita Zajdenverg, Carlos A Negrato
{"title":"Is there a role for platelet indices in predicting poor glucoregulation in type 2 diabetes mellitus?","authors":"Gabriel Araújo Medeiros, Jan B Felinto de Santana, Lenita Zajdenverg, Carlos A Negrato","doi":"10.4239/wjd.v16.i6.101173","DOIUrl":null,"url":null,"abstract":"<p><p>In this editorial, we discuss the recent article by Regassa <i>et al,</i> published in the <i>World Journal of Diabetes</i>, which highlights the potential role of platelet indices (PI) in predicting poor glucoregulation in patients with type 2 diabetes mellitus (T2DM). Given the high morbidity and mortality associated with T2DM, there is a constant need to find new and accessible methods for predicting and treating individuals with this condition. The pathophysiology of T2DM involves systemic inflammation, metabolic dysfunction, and an increased risk of vascular injury, which are commonly associated with the development of microvascular and macrovascular complications, such as cardiovascular diseases and neuropathies. The link between these complications and T2DM requires further elucidation but may be explained by prolonged exposure to high glycemic levels and increased advanced glycation end products. PI might play an important role in determining whether some individuals are prone to poor glucoregulation. Recent evidence encourages the scientific efforts to demonstrate the consistency of this role and its applicability in monitoring glucoregulation, underscoring the importance of the study by Regassa <i>et al.</i></p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 6","pages":"101173"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179910/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v16.i6.101173","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
In this editorial, we discuss the recent article by Regassa et al, published in the World Journal of Diabetes, which highlights the potential role of platelet indices (PI) in predicting poor glucoregulation in patients with type 2 diabetes mellitus (T2DM). Given the high morbidity and mortality associated with T2DM, there is a constant need to find new and accessible methods for predicting and treating individuals with this condition. The pathophysiology of T2DM involves systemic inflammation, metabolic dysfunction, and an increased risk of vascular injury, which are commonly associated with the development of microvascular and macrovascular complications, such as cardiovascular diseases and neuropathies. The link between these complications and T2DM requires further elucidation but may be explained by prolonged exposure to high glycemic levels and increased advanced glycation end products. PI might play an important role in determining whether some individuals are prone to poor glucoregulation. Recent evidence encourages the scientific efforts to demonstrate the consistency of this role and its applicability in monitoring glucoregulation, underscoring the importance of the study by Regassa et al.
期刊介绍:
The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.